Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Nature Biotechnology volume 38, pages 385–388 (2020)
3415
11
11
Metrics details
One of the most intensively investigated molecular targets in oncology proves its therapeutic worth for thyroid eye disease.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Oncogene Open Access 26 February 2022
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
£14.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Somerville, MA, USA
Elie Dolgin
You can also search for this author in PubMed Google Scholar
Reprints and permissions
Dolgin, E. IGF-1R drugs travel from cancer cradle to Graves’. Nat Biotechnol 38, 385–388 (2020). https://doi.org/10.1038/s41587-020-0481-8
Download citation
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0481-8
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Oncogene (2022)
Advertisement
© 2024 Springer Nature Limited
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.
About The Author
More Stories
Community Snapshot—April
Anatomy of a Scam
Climate and Environmental Sustainability Within the IETF and IRTF